Shilpa Medicare receives EIR from USFDA for R&D unit at Modavalasa

22 Apr 2019 Evaluate

Shilpa Medicare’s Pharmaceutical Research & Development (R&D) Unit at Modavalasa in the state of Andhra Pradesh region has received US Food and Drug Administration (USFDA) Establishment Inspection Report (EIR) with intimation of closure of inspection on April 08, 2019.

Earlier, this R&D site has undergone an inspection by the USFDA during February 11, 2019 to February 13, 2019, wherein the company has been issued a Form 483 with one observation.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

324.75 -1.20 (-0.37%)
17-Dec-2025 15:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.00
Dr. Reddys Lab 1272.55
Cipla 1496.30
Zydus Lifesciences 917.95
Lupin 2111.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×